In order to identify possible mechanisms of resistance to anti-EGFR MoAbs in CRC, we analyzed tumor samples from 21 KRAS/NRAS/BRAF/PIK3CA wt mCRC patients enrolled in the CAPRI-GOIM clinical trial by targeted sequencing (Table S1). This evidence concerns the gene NRAS and colorectal carcinoma.